The Scripps Research Institute Patent applications |
Patent application number | Title | Published |
20160115232 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF - Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells. The bispecific antibodies may be used to treat a disease or condition (e.g., cancer, autoimmune disease, pathogenic infection, inflammatory disease). The bispecific antibodies may be used to modulate (e.g., stimulate or suppress) an immune response. | 04-28-2016 |
20160002139 | OXIDATION OF ALKANES TO ALCOHOLS - The invention provides processes and materials for the efficient and cost-effective functionalization of alkanes, such as methane from natural gas, to provide esters, alcohols, and other compounds. The method can be used to produce liquid fuels such as methanol from a natural gas methane-containing feedstock. The soft oxidizing electrophile, a compound of a main group, post-transitional element such as Tl, Pb, Bi, and I, that reacts to activate the alkane C—H bond can be regenerated using inexpensive regenerants such as hydrogen peroxide, oxygen, halogens, nitric acid, etc. Main group compounds useful for carrying out this reaction includes haloacetate salts of metals having a pair of available oxidation states, such as Tl, Pb, Bi, and I. The inventors herein believe that a unifying feature of many of the MXn electrophiles useful in carrying out this reaction, such as Tl, Pb, and Bi species, is their isoelectronic configuration in the alkane-reactive oxidation state; the electrons having the configuration [Xe]4f145d10, with an empty 6s orbital. However, the iodine reagents have a different electronic configuration. | 01-07-2016 |
20150377879 | PEPTOIDS THAT BIND SPECIFIC ANTIGENS - Combinatorial libraries were generated providing a vast number of diverse peptoid ligands. From these libraries, ligands were identified which specifically bind molecules associated with autoimmune diseases, such as antibodies specific to aquaporin-4 (AQP4), binding of which to AQP4 causes the autoimmune disease, Neuoromyelitis Optica. Methods of generating peptoid libraries and for diagnosing Neuromyelitis Optica are also provided. | 12-31-2015 |
20150232432 | COPPER-CATALYSED LIGATION OF AZIDES AND ACETYLENES - A copper catalyzed click chemistry ligation process is employed to bind azides and terminal acetylenes to provide 1,4-disubstituted 1,2,3-triazole triazoles. The process comprises contacting a solution of an organic azide and a terminal alkyne with a source of catalytic Cu(I) ion to form a 1,4-disubstituted 1,2,3-triazole, wherein the source of Cu(I) ion comprises Cu(II) and a metal capable of reducing Cu(II) to Cu(I). In some embodiments, the metal capable of reducing Cu(II) to Cu(I) is selected from the group consisting of Al, Be, Co, Cr, Fe, Mg, Mn, Ni, and Zn. | 08-20-2015 |
20150094275 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE - The present invention provides novel heteroaryl compounds having a pyrimidine-containing core that is linked to a 4-trifluoromethoxyphenyl group via an amine linker. Such compounds are useful for the treatment of cancers. | 04-02-2015 |
20150031895 | COPPER-CATALYSED LIGATION OF AZIDES AND ACETYLENES - A copper catalyzed click chemistry ligation process is employed to bind azides and terminal acetylenes to provide 1,4-disubstituted 1,2,3-triazole triazoles. The process comprises contacting an organic azide and a terminal alkyne with a source of reactive Cu(I) ion in human blood plasma to form by cycloaddition a 1,4-disubstituted 1,2,3-triazole. The source of reactive Cu(I) ion can be, for example, a Cu(I) salt, Cu(II) ion in the presence of a reducing agent, or copper metal. | 01-29-2015 |
20140336056 | NON-INVASIVE EARLY DETECTION OF SOLID ORGAN TRANSPLANT REJECTION BY QUANTITATIVE ANALYSIS OF MIXTURES BY DEEP SEQUENCING OF HLA GENE AMPLICONS USING NEXT GENERATION SYSTEMS - The invention is a method of detecting or assessing solid organ graft (transplant) rejection by detecting donor-specific HLA alleles in a blood sample of a graft (transplant) recipient. The invention further comprises a method of detecting the presence of maternal cells in a blood sample of an offspring. | 11-13-2014 |
20140328795 | VIRUCIDAL SMALL MOLECULE AND USES THEREOF - In an embodiment of the present disclosure there is provided a method of inactivating enveloped DNA virus particles in a biological sample. In an embodiment, such a method comprises contacting the biological sample with an effective amount of an antiviral composition comprising PD 404,182 In some embodiments, the DNA virus is the Herpes Simplex virus-1 (HSV-1) or the Herpes Simplex Virus-2 (HSV-2). In another embodiment of the present disclosure, there is provided a method of treating, preventing, or reducing a viral infection caused by an enveloped DNA virus in a subject in need thereof. In yet another embodiment, there is provided a method of preventing transmission of a viral infection to a subject in need thereof. In an embodiment, such a method comprises contacting a mucus membrane of the subject with a topical formulation comprising an effective amount of PD 404,182 in combination with a pharmaceutically acceptable carrier | 11-06-2014 |
20140322269 | ENGINEERED OUTER DOMAIN (EOD) OF HIV GP120 AND MUTANTS THEREOF - The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings. | 10-30-2014 |
20140322249 | DNA VACCINES AGAINST TUMOR GROWTH AND METHODS OF USE THEREOF - A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a DNA construct operably encoding a cancer-associated Inhibitor of Apoptosis-family protein and an immunoactive gene product, such as a cytokine or a ligand for a natural killer cell surface receptor, in a pharmaceutically acceptable carrier. A preferred cytokine is CCL21. Preferred ligands for a natural killer cell surface receptor include human MICA, human MICB, human ULBP1, human ULBP2, and human ULBP3. The cancer-associated Inhibitor of Apoptosis (IAP)-family protein is preferably a survivin protein or livin protein. Method of inhibiting tumor growth by administering the vaccine of the invention to a mammal is also described. | 10-30-2014 |
20140302081 | HIV-1 GP120 MINI V3 LOOP AND USES THEREOF - The invention relates to an immunogenic HIV-1 gp120 mini V3 loop, which is a truncated version of the full-length gp120 V3 loop useful for crystallization with antibodies that recognize carbohydrate moieties. The invention also relates to the structure of a broadly neutralizing antibody as a complex with a glycosylated gp120 outer domain, as determined by crystallographic techniques, and the confirmation that a glycosylated gp120 outer domain has a functional relevant conformation, as well as the determination of key residues on a glycosylated gp120 outer domain, and uses thereof and compounds and compositions therefrom. Furthermore, the invention also relates to other peptides and mimetic peptides, which bind to broadly neutralizing antibodies. | 10-09-2014 |
20140287942 | Methods and Devices for Detection and Acquisition of Biomarkers - The present invention provides devices and methods for detecting and capturing molecular biomarkers from a subject in situ. Specifically, the devices contain an array of microneedles to which are attached probes specific for one or more biomarkers of interest. The devices can be used directly on a subject (e.g., via skin piercing) in detecting the biomarkers in the body of the subject (e.g., tissues, blood stream). | 09-25-2014 |
20140273214 | STEM CELL CULTURES - The present invention relates compounds for stabilizing cells and methods of their use. | 09-18-2014 |
20140273209 | ARTIFICIAL IMMUNE SYSTEM: METHODS OF USE - The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system. | 09-18-2014 |
20140271955 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS - Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes. | 09-18-2014 |
20140271488 | Chiral compounds of varying conformational rigidity and methods of synthesis - Synthesis of compounds having varying degrees of conformational rigidity is obtained via a low cost, high yield and efficient synthetic reactions. The library of compounds is structurally diverse having at least one or more chiral centers and providing large numbers of compounds having building block diversity and substantial scaffold diversity. The compounds further provide a novel method for obtaining candidate therapeutic agents for prevention, treatment or diagnosis of diseases. | 09-18-2014 |
20140233797 | IMAGE ANALYSIS PLATFORM FOR IDENTIFYING ARTIFACTS IN SAMPLES AND LABORATORY CONSUMABLES - A High-resolution Image Acquisition and Processing Instrument (HIAPI) performs at least five simultaneous measurements in a noninvasive fashion, namely: (a) determining the volume of a liquid sample in welh (or microtubes) containing liquid sample, (b) detection of precipitate, objects of artifacts within microliter plate wells, (c) classification of colored samples in microliter plate wells or microtubes; (dl determination of contaminant (e.g. wafer concentration}; (e) air bubbles; (f) problems with the actual plate. Remediation of contaminant is also possible. | 08-21-2014 |
20140212458 | NOVEL HIV-1 ENVELOPE GLYCOPROTEIN - The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron micrsocopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention. | 07-31-2014 |
20140205612 | HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES - The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided. | 07-24-2014 |
20140187554 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR - The invention provides small molecule modulators of retinoic acid receptor-related orphan receptors such as RORα, RORβ, or RORγ. Compounds of the invention can be effective modulators at concentrations ineffective to act on LXR receptors, or on other nuclear receptors, or other biological targets. Methods of modulation the RORs and methods of treating metabolic disorders, immune disorders, cancer, and CNS disorders wherein modulation of an ROR is medically indicated are also provided. | 07-03-2014 |
20140186378 | GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NKT CELLS - This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses. | 07-03-2014 |
20140170704 | Production of Carrier-Peptide Conjugates Using Chemically Reactive Unnatural Amino Acids - Provided are methods of making carrier polypeptide that include incorporating a first unnatural amino acid into a carrier polypeptide variant, incorporating a second unnatural amino acid into a target polypeptide variant, and reacting the first and second unnatural amino acids to produce the conjugate. Conjugates produced using the provided methods are also provided. In addition, orthogonal translation systems in methylotrophic yeast and methods of using these systems to produce carrier and target polypeptide variants comprising unnatural amino acids are provided. | 06-19-2014 |
20140134753 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES - Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed. | 05-15-2014 |
20140127200 | Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains - Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described. | 05-08-2014 |
20140127183 | HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS - Methods of enhancing angiogenesis utilizing carboxy-terminal truncated human tyrosyl-tRNA synthetase (TyrRS) are disclosed. The truncated human TyrRS polypeptides comprise residues 1-364 or residues 1-343 of full length human TyrRS (SEQ ID NO: 2). | 05-08-2014 |
20140114070 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS - The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense. | 04-24-2014 |
20140113012 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS - The present invention provides compounds and compositions for the amelioration of arthritis and joint injuries by inducing mesenchymal stem cells into chondrocytes. | 04-24-2014 |
20140093518 | Chemically Programmed Vaccination - Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with a targeting compound. | 04-03-2014 |
20140086871 | ULTRALONG COMPLEMENTARITY DETERMINING REGIONS AND USES THEREOF - Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject. | 03-27-2014 |
20140066632 | COPPER-CATALYSED LIGATION OF AZIDES AND ACETYLENES - A copper catalyzed click chemistry ligation process is employed to bind azides and terminal acetylenes to provide 1,4-disubstituted 1,2,3-triazole triazoles. The process comprises contacting an organic azide and a terminal alkyne with a source of reactive Cu(I) ion in human blood plasma to form by cycloaddition a 1,4-disubstituted 1,2,3-triazole. The source of reactive Cu(I) ion can be, for example, a Cu(I) salt, Cu(II) ion in the presence of a reducing agent, or copper metal. | 03-06-2014 |
20140051085 | DIRECT REPROGRAMMING OF HUMAN FIBROBLASTS TO FUNCTIONAL NEURONS UNDER DEFINED CONDITIONS - The present invention provides methods of generating a neuronal cell from a differentiated non-neuronal cell by increasing the amount of a miR-124 microRNA, a MYT1L transcription factor, and a BRN2 transcription factor in the differentiated non-neuronal cell. | 02-20-2014 |
20140050720 | ULTRALONG COMPLEMENTARITY DETERMINING REGIONS AND USES THEREOF - Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject. | 02-20-2014 |
20140045800 | TETRACYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE - Certain tetracyclic compounds are described, which may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis). | 02-13-2014 |
20140045723 | Method of Enhancing Enzyme Activity - Described are methods and means for enhancing enzyme activity toward insoluble substrates. This is achieved by means of in vitro compartmentalization in which an insoluble microparticle functions both as the enzyme substrate and as a structure for negative selection. Enhanced enzymes expressed from a microparticle-linked polynucleotide library preferentially degrade the microparticle releasing specific gene variants into solution. Gene variants encoding less active enzyme variants remain linked to the microparticle and may be removed through centrifugation, thus enriching the polynucleotide library for more active enzyme variants. These methods may be used to enhance cellulase and ligninase activity toward insoluble cellulosic biomass. | 02-13-2014 |
20140039156 | HIGH-THROUGHPUT SCREENING FOR COMPOUNDS MODULATING EXPRESSION OF CELLULAR MACRO-MOLECULES - A method of screening for compounds that module expression of specific macromolecules, the “target”. The method is particularly useful in that it does not require separation of target-bound and excess ligand and therefore enables, but is not limited to, High Throughput Screening for compounds that increase or decrease the levels or amounts of a target present in a biological sample. The method can also be used for high-throughput diagnosis of a condition leading to an increase or decrease of a cellular macromolecule. | 02-06-2014 |
20140038949 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE - The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided. | 02-06-2014 |
20140037693 | 6"-AMINO-6"-DEOXYGALACTOSYLCERAMIDES - This invention relates to galactosylceramide compounds. | 02-06-2014 |
20140018566 | PALLADIUM(II)-CATALYZED SELECTIVE FLUORINATION OF BENZOIC ACIDS AND DERIVATIVES - A new method of ortho-fluorination for selectively fluorinating a benzoic acid or derivative compound where an aryl C—H bond is directly replaced by an aryl C—F bond is provided. The method comprises reacting a compound having the formula: | 01-16-2014 |
20130344564 | Vault Complexes for Facilitating Biomolecule Delivery - The invention relates to compositions of vault complexes containing recombinant membrane lytic proteins, such as an adenovirus protein VI lytic domain, and methods of using the vault complexes to facilitate delivery and entry of a biomolecule into a cell or subject. | 12-26-2013 |
20130338196 | ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING - Compounds are disclosed that are effective in inhibition of fatty acid amide hydrolase, an enzyme responsible for catabolism of endogenous cannabinoids such as anandamide. The compounds are useful as analgesic compounds and as sleep-inducing compounds, that can be orally administered, and that can have a relatively long duration of effect. Methods of preparation of the compounds are also provided. The compounds are conformationally constrained analogs of heterocyclylketones such as oxazolylketones. | 12-19-2013 |
20130309720 | Methods and Compositions for the Production of Orthogonal tRNA-Aminoacyl tRNA Synthetase Pairs - This invention provides compositions and methods for generating components of protein biosynthetic machinery including orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases. Methods for identifying orthogonal pairs are also provided. These components can be used to incorporate unnatural amino acids into proteins in vivo. | 11-21-2013 |
20130295111 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH HYPERACTIVE IMMUNE SYSTEM - The present invention provides methods and compositions for treating disorders associated with hyperactive immune responses. The invention also provides methods for lithibiting activation of CD4 | 11-07-2013 |
20130281453 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES - Serine hydrolases are implicated in malconditions such as cancer, central nervous system disorders, cardiovascular disorders, obesity, and metabolic disorders. Many serine hydrolases expressed in proteomic libraries are of unknown function in vivo. Compounds identified through library versus library screening can be used for treatment of malconditions associated with the specific serine hydrolase KIAA1363 (also known as AADACL1). A library of inhibitors of KIAA1363 was prepared and candidate compounds were identified as a potent inhibitors having submicromolar IC | 10-24-2013 |
20130281443 | INHIBITORS OF FOCAL ADHESION KINASE - The invention provides inhibitors of focal adhesion kinase, an enzyme involved in the attachment of the cytoskeleton of a cell to an extracellular matrix, which has been implicated in processes such as cell migration, cell proliferation, and cell survival. The inhibitors are derivatives of a 5-substituted 2,4-diaminopyridine wherein the substituents are as defined herein. The invention also provides a method of using the inhibitors in treatment of cancer, and methods of preparation of the inhibitors by use of coupling reactions. | 10-24-2013 |
20130280809 | REPROGRAMMING OF CELLS TO A NEW FATE - Methods and compositions for transdifferentiation of an animal cell from (i) a first pluripotent cell fate to a second nonpluripotent cell fate or (ii) from a non-pluripotent mesodermal, endodermal, or ectodermal cell fate to a different non-pluripotent mesodermal, endodermal, or ectodermal cell fate. | 10-24-2013 |
20130252259 | Methods for the Detection of Circulating Tumor Cells - The present invention provides methods for revealing, detecting, and analyzing circulating tumor cells in the blood of a subject. Revealing detectable circulating tumor cells allows for early stage detection and diagnosis in addition to long term prognosis in subjects with cancer. Additionally, enrichment allows for robust detection and clinically meaningful analysis of low volume samples for use in clinical settings as well as innovative methods for the treatment of cancers. | 09-26-2013 |
20130251726 | NOVEL HIV -1 BROADLY NEUTRALIZING ANTIBODIES - The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided. | 09-26-2013 |
20130245230 | Unnatural Reactive Amino Acid Genetic Code Additions - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided. | 09-19-2013 |
20130244245 | Orthogonal Translation Components for the in Vivo Incorporation of Unnatural Amino Acids - The invention relates to orthogonal pairs of tRNAs and aminoacyl-tRNA synthetase that can incorporate unnatural amino acid into proteins produced in eubacterial host cells such as | 09-19-2013 |
20130231336 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS - The present invention provides novel substituted pyrimidinyl-amines that are useful as inhibitors of protein kinases, especially c-Jun N-terminal kinases (JNK) and pharmaceutical compositions thereof and methods of using the same for treating conditions responsive to the inhibition of the JNK pathway. | 09-05-2013 |
20130217679 | Compositions and Methods for Treatment of Neurodegenerative Disease - Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed. | 08-22-2013 |
20130210918 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS - The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors. | 08-15-2013 |
20130210117 | CRYSTALS OF MEMBRANE PROTEINS - A polypeptide in crystalline form comprises a G-protein coupled receptor (GPCR) with an IC3 loop substituted by an amino acid residue sequence of lysozyme. | 08-15-2013 |
20130203793 | Protection and Treatment Against Influenza Infection - Method and composition for protection and treatment against influenza viral infection by modulating the activity of at least one essential host signaling pathways, including the Hedgehog (Hh), the Bone Morphogenetic Protein (BMP), the Notch (N) signaling pathways or combinations thereof, which activity is altered by the viral protein NS1. The method and composition comprise use of a compound that modulates at least one of these essential host signaling pathways for preventing or controlling symptoms associated with influenza viral infection. The method or composition can also be used either alone or in combination with other therapeutic agents for treating or protecting against influenza infection, and associated syndromes. | 08-08-2013 |
20130196989 | COMPOSITIONS AND METHODS FOR INDUCING CELL DEDIFFERENTIATION - The present invention provides compounds, compositions and methods for dedifferentiating lineage committed mammalian cells into stem cells. The present invention also provides methods of inducing dedifferentiation of lineage committed mammalian cells into stem cells, which can be further differentiated into various lineage committed cells. Methods of identifying additional compounds useful for inducing dedifferentiation of lineage committed cells into stem cells are also provided. | 08-01-2013 |
20130177581 | Compositions and Methods Related to mRNA Translational Enhancer Elements - Provided are mRNA translational enhancer elements (TEEs), e.g., SEQ ID NOs:1-35. Also provided are translational enhancer polynucleotides that comprise one or more of the specific TEEs exemplified herein or their variants, homologs or functional derivatives. Further provided are expression vectors comprising such TEEs or translational enhancer polynucleotides, as well as host cells and expression systems that harbor such vectors. | 07-11-2013 |
20130171074 | TARGETING COMPOUNDS - The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided. | 07-04-2013 |
20130164758 | Enzyme Regulating Ether Lipid Signaling Pathways - A multidimensional profiling strategy that combines activity-based proteomics and metabolomics was used to determine that an active protein, which is a previously uncharacterized enzyme highly elevated in aggressive cancer cells, serves as a central node in an ether lipid signaling network that bridges platelet-activating factor and the lysophospholipids. Biochemical studies confirmed that the active protein regulates this pathway by hydrolyzing the metabolic intermediate 2-acetyl monoalkylglycerol. Inactivation of the active protein disrupted ether lipid metabolism in cancer cells and impaired cell migration and tumor growth in vivo. | 06-27-2013 |
20130156762 | Mechanically-Activated Cation Channels - Methods of screening for agents that modulate the activity of a mechanically-activated cation channel are provided. Also provided are compositions and methods for ameliorating pain by antagonizing or inhibiting mechanically-activated cation channels. | 06-20-2013 |
20130078656 | ARTIFICIAL IMMUNE SYSTEM: METHODS OF USE - The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system. | 03-28-2013 |
20130065875 | SMALL MOLECULE INHIBITORS OF HEPATITIS C VIRUS - The invention provides derivatives and analogues of triazatetracyclo[7.7.0.0 | 03-14-2013 |
20130059385 | METHODS OF GENERATING PLURIPOTENT STEM CELLS - Disclosed are methods, compositions, and kits of producing an induced pluripotent stem cell from a mammalian non-pluripotent cell that does not endogenously or heterologously express Sox2 and is not in contact with a Sox2 polypeptide. | 03-07-2013 |
20130053428 | NATURAL ANTISENSE AND NON-CODING RNA TRANSCRIPTS AS DRUG TARGETS - Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reduction). | 02-28-2013 |
20120329840 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS - Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided. | 12-27-2012 |
20120329839 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS - Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided. | 12-27-2012 |
20120329838 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS - Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided. | 12-27-2012 |
20120329162 | GENETICALLY ENCODED FLUORESCENT COUMARIN AMINO ACIDS - The invention relates to orthogonal pairs of tRNAs and aminoacyl-tRNA synthetases that can incorporate the coumarin unnatural amino acid L-(7-hydroxycoumarin-4-yl)ethylglycine into proteins produced in eubacterial host cells such as | 12-27-2012 |
20120309939 | Production of Therapeutic Proteins in Photosynthetic Organisms - The present disclosure relates to methods of expressing therapeutic proteins in photosynthetic organisms and the therapeutic proteins produced by the methods. The therapeutic proteins include high-mobility group box 1 (HMGB1) protein, fibronectin domain (10) (10FN3), fibronectin domain (14) (14FN3), interferon beta (IFNβ), proinsulin and vascular endothelial growth factor (VEGF). The photosynthetic organisms include prokaryotes such as cyanobacteria and eukaryotes such as alga and plants. Transformation of eukaryotes is preferably the plastid genome, more preferably the chloroplast genome. | 12-06-2012 |
20120309014 | HIGH THROUGHPUT SCREENING OF GENETICALLY MODIFIED PHOTOSYNTHETIC ORGANISMS - The present invention provides a method and compositions for high throughput screening of genetically modified photosynthetic organisms for plasmic state. The present invention provides methods of producing one or more proteins, including biomass degrading enzymes in a plant. Also provided are the methods of producing biomass degradation pathways in alga cells, particularly in the chloroplast. Single enzymes or multiple enzymes may be produced by the methods disclosed. The methods disclosed herein allow for the production of biofuel, including ethanol. | 12-06-2012 |
20120302607 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES - The invention provides a series of C4-substituted oxazole compounds having an alpha keto side chain at the 2 position, for example, compounds of formula I. The compounds can inhibit fatty acid amide hydrolase and can be useful for treatment of malconditions modulated by fatty acid amide hydrolase. The invention further provides methods of making compounds of formula I, useful intermediates in the preparation of compounds of formula I, and methods of using compounds of formula 1 and compositions thereof. | 11-29-2012 |
20120288913 | NOVEL FUSION PARTNERS FOR THE PURPOSE OF CRYSTALLIZING G-PROTEIN COUPLED RECEPTORS - GPCR-fusion partner proteins comprising G protein coupled receptors (GPCRs) of GPCRs and fusion partners such as rubredoxin, cytochrome b562 RIL (Bril, bRIL, BRIL), T4 lysozyme C-terminal fragment (Cterm-T4L), flavodoxin, or xylanase either substituted for some or all of the third intracellular loop of the GPCR between the fifth and sixth helix of the GPCR are described or attached to an terminus or C terminus of the GPCR. GPCR-fusion partner proteins in crystalline form, optionally of a quality suitable for x-ray crystallographic structure determination of the GPCR, are described. Methods of using fusion partners in GPCR-fusion partner proteins to support crystallization of GPCR-fusion partner proteins for x-ray crystallographic structure determination of the GPCR, are described. Methods of identifying other suitable fusion partners through screening of protein data banks are also described. | 11-15-2012 |
20120282689 | Expanding the Eukaryotic Genetic Code - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided. | 11-08-2012 |
20120282668 | Genetically Programmed Expression of Proteins Containing the Unnatural Amino Acid Phenylselenocysteine - The invention relates to orthogonal pairs of tRNAs and aminoacyl-tRNA synthetase that can incorporate the unnatural amino acid phenylselenocysteine into proteins produced in eubacterial host cells such as | 11-08-2012 |
20120282626 | Selective Incorporation of 5-hydroxytryptophan into Proteins in Mammalian Cells - This invention provides methods and compositions for incorporation of an unnatural amino acid into a peptide using an orthogonal aminoacyl tRNA synthetase/tRNA pair. In particular, an orthogonal pair is provided to incorporate 5-hydroxy-L-tryptophan in a position encoded by an opal mutation. | 11-08-2012 |
20120270815 | MODIFIED-GALACTOSYL CERAMIDES FOR STAINING AND STIMULATING NATURAL KILLER T CELLS - Modified glycolipid compounds are provided. Also disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, and methods suitable for labeling NKT cells. | 10-25-2012 |
20120264218 | INDUCTION OF PLURIPOTENT CELLS - The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells. | 10-18-2012 |
20120263702 | Human Aminoacyl-tRNA Synthetase Polypeptides Useful For The Regulation of Angiogenesis - Pharmaceutical compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis an nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed. | 10-18-2012 |
20120258142 | GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NKT CELLS - This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses. | 10-11-2012 |
20120253026 | Expanding the Eukaryotic Genetic Code - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided. | 10-04-2012 |
20120252067 | Systems for the Expression of Orthogonal Translation Components in Eubacterial Host Cells - The invention related to compositions and methods for the in vivo production of polypeptides comprising one or more unnatural amino acids. Specifically, the invention provides plasmid systems for the efficient eubacterial expression of polypeptides comprising one or more unnatural acids at genetically-programmed positions. | 10-04-2012 |
20120231517 | MINIATURIZED ELECTROPORATION-READY MICROWELL ARAY FOR HIGH-THROUGHPUT GENOMIC SCREENING - Methods of introducing exogenous molecules into cells including cell lines and primary cells are provided. Additionally, miniaturized electroporation-ready microwell arrays are provided. These tools provide a miniaturized high-throughput functional genomics screening platform to carry out genome-size screens in a variety of cell types. | 09-13-2012 |
20120225087 | NICOTINE HAPTENS, IMMUNOCONJUGATES AND THEIR USES - The present invention provides novel nicotine hapten compounds and nicotine immunoconjugates which can be used for in vivo production of antibodies that specifically bind to nicotine. The invention also provides methods of using vaccines comprising the nicotine immunoconjugates in active or passive immunization protocols. The compositions and methods of the invention are useful for prevention and treatment of nicotine addiction. | 09-06-2012 |
20120202243 | IN Vivo Incorporation of Unnatural Amino Acids - The invention provides methods and compositions for in vivo incorporation of unnatural amino acids. Also provided are compositions including proteins with unnatural amino acids. | 08-09-2012 |
20120184018 | Genetically Programmed Expression of Selectively Sulfated Proteins in Eubacteria - The invention relates to orthogonal pairs of tRNAs and aminoacyl-tRNA synthetases that can incorporate the unnatural amino acid sulfotyrosine into proteins produced in eubacterial host cells such as | 07-19-2012 |
20120178642 | GENE EXPRESSION PROFILES ASSOCIATED WITH CHRONIC ALLOGRAFT NEPHROPATHY - By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and/or interstitial fibrosis and tubular atrophy CAN/IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and/or subtyping of CAN/IFTA. | 07-12-2012 |
20120178158 | ADULT ANIMALS GENERATED FROM INDUCED PLURIPOTENT CELLS - The present invention provides methods and compositions for generating and using induced pluripotent stem cells. | 07-12-2012 |
20120177644 | MESENCHYMAL STEM CELL DIFFERENTIATION - The present invention provides for methods and compositions for treating or preventing arthritis and joint injury. | 07-12-2012 |
20120165542 | COPPER-CATALYSED LIGATION OF AZIDES AND ACETYLENES - A copper catalyzed click chemistry ligation process is employed to bind azides and terminal acetylenes to provide 1,4-disubstituted 1,2,3-triazole triazoles. The process comprises contacting an organic azide and a terminal alkyne with a source of reactive Cu(I) ion for a time sufficient to form by cycloaddition a 1,4-disubstituted 1,2,3-triazole. The source of reactive Cu(I) ion can be, for example, a Cu(I) salt or copper metal. The process is preferably carried out in a solvent, such as an aqueous alcohol. Optionally, the process can be performed in a solvent that comprises a ligand for Cu(I) and an amine. | 06-28-2012 |
20120157457 | COMPOSITIONS AND METHODS FOR INDUCING NEURONAL DIFFERENTIATION - The present invention provides compositions and methods for inducing neuronal cell differentiation. | 06-21-2012 |
20120156237 | Novel Antitoxin and Vaccine Platform Based on Nodavirus VLPS - Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided. | 06-21-2012 |
20120129215 | Compositions of Orthogonal Lysyl-tRNA and Aminoacyl-tRNA Synthetase Pairs and Uses Thereof - Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal lysyl-tRNAs, orthogonal lysyl-aminoacyl-tRNA synthetases, and orthogonal pairs of lysyl-tRNAs/synthetases, which incorporate homoglutamines into proteins are provided in response to a four base codon. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with homoglutamines using these orthogonal pairs. | 05-24-2012 |
20120123092 | HUMAN A2A ADENOSINE RECEPTOR CRYSTALS AND USES THEREOF - The invention provides the structure of human A2A adenosine receptor protein bound to an antagonist. Methods of using one or more binding sites and other features of this G-protein coupled receptor to develop new therapeutics are also disclosed. | 05-17-2012 |
20120107853 | Use of Genetically Modified Organisms to Generate Biomass Degrading Enzymes - The present invention provides a method and compositions for high throughput screening of genetically modified photosynthetic organisms for plasmic state. The present invention provides methods of producing one or more proteins, including biomass degrading enzymes in a plant. Also provided are the methods of producing biomass degradation pathways in alga cells, particularly in the chloroplast. Single enzymes or multiple enzymes may be produced by the methods disclosed. The methods disclosed herein allow for the production of biofuel, including ethanol. | 05-03-2012 |
20120101006 | Methods and Compositions for the Production of Orthogonal tRNA-Aminoacyl tRNA Synthetase Pairs - This invention provides compositions and methods for generating components of protein biosynthetic machinery including orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases. Methods for identifying orthogonal pairs are also provided. These components can be used to incorporate unnatural amino acids into proteins in vivo. | 04-26-2012 |
20120100593 | Crystals of membrane proteins - A polypeptide in crystalline form comprises a G-protein coupled receptor (GPCR) with an IC3 loop substituted by an amino acid residue sequence of lysozyme. | 04-26-2012 |
20120100570 | Site-Specific Incorporation of Redox Active Amino Acids into Proteins - Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases, which incorporate redox active amino acids into proteins are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with redox active amino acids using these orthogonal pairs. | 04-26-2012 |
20120065237 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES - Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed. | 03-15-2012 |
20120058114 | ERBB2 antibodies comprising modular recognition domains - Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described. | 03-08-2012 |
20120039931 | DNA COMPOSITION ENCODING AN IMMUNOGENIC VEGF RECEPTOR PEPTIDE AND METHODS OF USE THEREOF - A method of inhibiting endothelial cell proliferation in a mammal is provided. The method comprises the step of administering to the mammal an effective immunological response eliciting amount of a DNA composition comprising a DNA construct operably encoding a VEGF receptor polypeptide and a pharmaceutically acceptable carrier therefor, whereby said mammal exhibits an immune response elicited by vaccine and specific to proliferating endothelial cells. The methods of this invention inhibit vascular endothelial cell proliferation in the tumor micro-environment. Angiogenesis inhibition and subsequent decrease in tumor growth and dissemination is achieved. | 02-16-2012 |
20120039891 | Methods for diagnosing cancer and decreasing metastasis by cancer cells - The invention provides a protein that is a tumor marker protein. This protein can be used to prepare antibodies that bind to the tumor marker protein. These antibodies can be used to reduce, or eliminate metastasis by cancer cells that produce the tumor marker protein. In addition, the invention provides methods that can be used to diagnose cancer, and metastasis by cancer cells. | 02-16-2012 |
20120034211 | EGFR antibodies comprising modular recognition domains - Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described. | 02-09-2012 |
20120028351 | GENERATION AND MAINTENANCE OF STEM CELLS - The present invention provides for the generation and maintenance of pluripotent cells by culturing the cells in the presence of an ALK5 inhibitor. | 02-02-2012 |
20120020967 | VEGF antibodies comprising modular recognition domains - Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described. | 01-26-2012 |
20120020966 | Multispecific antibody targeting and multivalency through modular recognition domains - Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described. | 01-26-2012 |
20120014938 | Angiogenic Tyrosyl t-RNA Synthetase Compositions and Methods - The present invention provides an isolated tyrosyl tRNA synthetase (TyrRS) polypeptide variant which comprises (a) a Rossmann fold region or a portion thereof, preferably including an α5 coil; and (b) an anticodon recognition domain or portion thereof, preferably including an α14 coil. Preferably, the α5 coil and the α14 coil have a greater spatial separation in the tertiary structure of the variant compared to the corresponding spatial separation in native human TyrRS. The variant preferably comprises an amino acid residue sequence identity of at least about 50% compared to the amino acid residue sequence of human TyrRS (SEQ ID NO: 3), includes at least one non-conservative amino acid residue substitution relative to the amino acid residue sequence of human TyrRS, and preferably presents an exposed ELR motif in the α5 coil on an external portion of the tertiary structure of the polypeptide. A preferred TyrRS protein variant comprises the amino acid residue sequence of SEQ ID NO: 4 or a portion thereof. The proteins and protein fragments of the invention are angiogenic and are useful for stimulating angiogenesis in mammalian tissues. | 01-19-2012 |
20120009166 | Isolated monocyte populations and related therapeutic applications - The invention provides methods of using isolated monocyte populations to treat subjects suffering from various ocular vascular disease or ocular degenerative disorders. The present invention also provides novel methods for isolating substantially pure monocyte populations. The methods involve extracting a blood sample or a bone marrow sample from a subject, debulking red blood cells from the sample, and then separating remaining red blood cells and other cell types in the sample from monocytes. Instead of using any selection or labeling agents, the red blood cells and other cell types are separated from monocytes based on their size, granularity or density. The isolated monocytes can be further activated in vitro or ex vivo prior to being administered to a subject. Isolated cell populations containing substantially pure CD14 | 01-12-2012 |
20120004183 | Unnatural reactive amino acid genetic code additions - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided. | 01-05-2012 |
20110318806 | SITE SPECIFIC INCORPORATION OF KETO AMINO ACIDS INTO PROTEINS - Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases, which incorporate keto amino acids into proteins are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with keto amino acids using these orthogonal pairs. | 12-29-2011 |
20110312908 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE - The present invention provides novel heteroaryl compounds that are linked to an aryl group via an amine linker. Such compounds are useful for the treatment of cancers. | 12-22-2011 |
20110311550 | AGENTS FOR HCV TREATMENT - Provided are polypeptides, including antibodies and fragments thereof, useful for preventing or treating new or recurring infection of hepatitis C virus, as well as methods of preventing or treating new or recurring hepatitis C viral infection. Also provided are modified E1 and E2 polypeptides. | 12-22-2011 |
20110311516 | Chemically Programmed Vaccination - Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with a targeting compound. | 12-22-2011 |
20110300147 | Inhibiting tumor cell invasion, metastasis and angiogenesis - The present invention relates to new compositions and methods useful for preventing, treating and diagnosing metastatic and/or invasive cancer and undesirable angiogenesis. For example, the invention relates to inhibitors of proteases that are specifically expressed in tumors, prodrugs activated in the tumor microenvironment and methods for using those inhibitors and prodrugs to inhibit angiogenesis and tumor cell invasion. | 12-08-2011 |
20110294761 | STEM CELL CULTURES - The present invention relates compounds for stabilizing cells and methods of their use. | 12-01-2011 |
20110275650 | METHODS AND COMPOSITIONS RELATED TO TARGETING MONOACYLGLYCEROL LIPASE - This invention provides compounds that selectively inhibit monoacylglycerol lipase (MAGL). The invention also provides methods of using the MAGL selective inhibitors to stimulate 2-Arachidonoylglycerol (2-AG) mediated endocannabinoid signaling in vivo, and to treat conditions that are associated with or linked to endocannabinoid signaling. The invention additionally provides methods of treating cancer or inhibiting tumor growth by targeting MAGL with MAGL specific inhibitors. The invention further provides methods of screening for MAGL inhibitors with improved biochemical and pharmaceutical properties. | 11-10-2011 |
20110255745 | IMAGE ANALYSIS PLATFORM FOR IDENTIFYING ARTIFACTS IN SAMPLES AND LABORATORY CONSUMABLES - A High-resolution Image Acquisition and Processing Instrument (HIAPI) performs at least five simultaneous measurements in a noninvasive fashion, namely: (a) determining the volume of a liquid sample in welh (or microtubes) containing liquid sample, (b) detection of precipitate, objects of artifacts within microliter plate wells, (c) classification of colored samples in microliter plate wells or microtubes; (dl determination of contaminant (e.g. wafer concentration}; (e) air bubbles; (f) problems with the actual plate. Remediation of contaminant is also possible. | 10-20-2011 |
20110229923 | CRYSTAL OF A CYTOCHROME-LIGAND COMPLEX AND METHODS OF USE - The teachings relates to the three-dimensional structure of a crystal of a cytochrome protein complexed with a ligand. The three-dimensional structure of four cytochrome P450 2A6-ligand complexes are disclosed. Cytochrome P450 2A6-ligand crystal structures, wherein the ligand is an inhibitor molecule, are useful for providing structural information that may be integrated into drug screening and drug design processes. Thus, the teachings also relate to methods for utilizing a crystal structure of a cytochrome P450 2A6-ligand complex for identifying, designing, selecting, or testing inhibitors of the cytochrome protein. Such inhibitors are useful as therapeutics for the treatment or modulation of i) diseases; ii) disease symptoms; or iii) the effect of other physiological events mediated by the cytochrome. | 09-22-2011 |
20110224233 | STEM CELL CULTURES - The present invention relates compounds for stabilizing cells and methods of their use. | 09-15-2011 |
20110217733 | Expanding the eukaryotic genetic code - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided. | 09-08-2011 |
20110183947 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS - The invention provides a series of -αketoheterocyclic compounds, for example, compounds of formula (I). The compounds can inhibit fatty acid amide hydrolase and can be useful for treatment of malconditions modulated by fatty acid amide hydrolase. The invention further provides methods of making compounds of formula (I), useful intermediates for the preparation of compounds of formula (I), and methods of using compounds of formula (I) and compositions thereof. | 07-28-2011 |
20110171226 | Novel Subtype of Closteridium Botulinum Neurotoxin Type A and Uses Thereof - A novel subtype of type A botulinum neurotoxin (BoNT/A) is disclosed in the application. Methods to purify the neurotoxin as well as uses thereof are also disclosed. | 07-14-2011 |
20110150833 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS - Compounds useful as Rho kinase inhibitors of formula (1) wherein the variables are as defined herein are provided. Methods of treatment of malconditions mediated by Rho kinase, and methods of preparation of the compounds, are also provided. | 06-23-2011 |
20110135645 | HUMAN ANTIBODIES NEUTRALIZING HUMAN METAPNEUMOVIRUS - The present invention discloses methods for generating antibodies to human metapneumovirus (HMPV) polypeptides, including antibodies that immunospecifically bind to a HMPV F-protein. The invention also discloses methods for preventing, treating, or ameliorating symptoms associated with HMPV infection. | 06-09-2011 |
20110124100 | TRANSLATION ENHANCER-ELEMENT DEPENDENT VECTOR SYSTEMS - A translation enhancer-driven positive feedback vector system is disclosed which is designed to facilitate identification of a Translational Enhancer Element (TEE) and to provide a means for overexpression of gene products. The system exploits both transcriptional and translational approaches to control the expression levels of genes and/or gene products. Methods are also disclosed for screening libraries of random nucleotide sequences to identify translational elements and for overproduction of proteins, which have uses in both research and industrial environments. | 05-26-2011 |
20110110917 | Human Aminoacyl-tRNA Synthetase Polypeptides Useful For The Regulation of Angiogenesis - Compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis, as well as nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed. | 05-12-2011 |
20110105764 | Copper-catalysed ligation of azides and acetylenes - A copper catalyzed click chemistry ligation process is employed to bind azides and terminal acetylenes to provide 1,4-disubstituted 1,2,3-triazole triazoles. The process comprises contacting an organic azide and a terminal alkyne with a source of reactive Cu(I) ion for a time sufficient to form by cycloaddition a 1,4-disubstituted 1,2,3-triazole. The source of reactive Cu(I) ion can be, for example, a Cu(I) salt or copper metal. The process is preferably carried out in a solvent, such as an aqueous alcohol. Optionally, the process can be performed in a solvent that comprises a ligand for Cu(I) and an amine. | 05-05-2011 |
20110098188 | BLOOD BIOMARKERS FOR PSYCHOSIS - A plurality of biomarkers determine the diagnosis of psychosis based on the expression levels in a sample such as blood. Subsets of biomarkers predict the diagnosis of delusion or hallucination. The biomarkers are identified using a convergent functional genomics approach based on animal and human data. Methods and compositions for clinical diagnosis of psychosis are provided. | 04-28-2011 |
20110086053 | Glycolipids And Analogues Thereof As Antigens For NKT Cells - This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses. | 04-14-2011 |
20110082106 | METHODS OF ACTIVATING NKT CELLS - Provided are methods of activating an NKT cell which include a step of contacting the NKT cell with a sufficient amount of isoglobotrihexosylceramide (iGb3) to induce secretion of a cytokine from the NKT cell, stimulate proliferation of the NKT cell or upregulate expression of a cell surface marker on the NKT cell. Methods of activating an NKT cell population in a subject are also provided. | 04-07-2011 |
20110077385 | Protein arrays - The invention provides proteins attached to solid supports, and methods of preparing such solid support-bound proteins are provided. The proteins are attached to solid supports by means of an unnatural amino acid incorporated into the protein, which unnatural amino acid includes a reactive group that can react with a second reactive group that is attached to a solid support. | 03-31-2011 |
20110060121 | METHOD OF PREPARING GLYCOPEPTIDES - A method is provided for the synthesis of glycopeptides using a sugar assisted ligation strategy, wherein an N-terminal peptide portion in the form of a thioester is coupled with a C-terminal peptide portion bearing a carbohydrate moiety comprising a thiol group. | 03-10-2011 |
20110052562 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS - Compounds useful as Rho kinase inhibitors according to formula IA or IB: wherein A, B, D, E, R | 03-03-2011 |
20110052525 | Breaking Immunological Tolerance with a Genetically Encoded Unnatural Amino Acid - The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against a version of a target moiety having one or more unnatural amino acid which antibody is cross reactive with the natural target moiety. | 03-03-2011 |
20110046121 | INHIBITORS OF FOCAL ADHESION KINASE - The invention provides inhibitors of focal adhesion kinase, an enzyme involved in the attachment of the cytoskeleton of a cell to an extracellular matrix, which has been implicated in processes such as cell migration, cell proliferation, and cell survival. The inhibitors are derivatives of a 5-substituted 2,4-diaminopyridine wherein the substituents are as defined herein. The invention also provides a method of using the inhibitors in treatment of cancer, and methods of preparation of the inhibitors by use of coupling reactions. | 02-24-2011 |
20110038835 | ANILIDES AND ANALOGS AS RHO KINASE INHIBITORS - Compounds useful as Rho kinase inhibitors of formula (I): wherein variable are as defined herein are provided. Methods of treatment of malconditions mediated by Rho kinase, and methods of preparation of the compounds, are also provided. | 02-17-2011 |
20110027867 | Methods and compositions for the production of orthogonal tRNA-aminoacyltRNA synthetase pairs - This invention provides compositions and methods for generating components of protein biosynthetic machinery including orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases. Methods for identifying orthogonal pairs are also provided. These components can be used to incorporate unnatural amino acids into proteins in viva | 02-03-2011 |
20110027323 | ADJUVANTS AND METHODS OF USE - Compositions comprising NKT cell agonist compounds and a physiologically acceptable vehicle are provided. Methods of stimulating an NKT cell and enhancing an immune response are also disclosed. Further provided are vaccine preparations comprising NKT cell agonist compounds. | 02-03-2011 |
20110008782 | Site-specific incorporation of redox active amino acids into proteins - Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases, which incorporate redox active amino acids into proteins are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with redox active amino acids using these orthogonal pairs. | 01-13-2011 |
20110008332 | Combination Therapy to Treat Persistent Viral Infections - The present invention pres ides combination therapies to treat persistent viral infections. In particular, combinations of vaccines and IL-10 or IL-10 receptor (IL-10R) antagonists to clear such infections are provided. | 01-13-2011 |
20100323968 | Process of inhibiting cell death in injured cartilage - Processes for inhibiting apoptotic cell death and glycosaminoglycan release from injured cartilage is provided. Inhibition is accomplished using caspase inhibitors. | 12-23-2010 |
20100298312 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS - The present invention provides novel substituted pyrimidinyl-amines that are useful as inhibitors of protein kinases, especially c-Jun N-terminal kinases (JNK) and pharmaceutical compositions thereof and methods of using the same for treating conditions responsive to the inhibition of the JNK pathway. | 11-25-2010 |
20100297693 | Production of carrier-peptide conjugates using chemically reactive unnatural amino acids - Provided are methods of making carrier polypeptide that include incorporating a first unnatural amino acid into a carrier polypeptide variant, incorporating a second unnatural amino acid into a target polypeptide variant, and reacting the first and second unnatural amino acids to produce the conjugate. Conjugates produced using the provided methods are also provided. In addition, orthogonal translation systems in methylotrophic yeast and methods of using these systems to produce carrier and target polypeptide variants comprising unnatural amino acids are provided. | 11-25-2010 |
20100291093 | ANTIBODY-MEDIATED DISRUPTION OF QUORUM SENSING IN BACTERIA - The invention provides an immunogenic molecular entity, a supramolecular assembly, and an antibody that can be used to inhibit Gram-positive bacterial quorum sensing, prevent infection or development of a disease condition associated with a Gram-positive bacterial infection. The invention also provides methods of inhibiting Gram-positive bacterial quorum sensing, and methods of preventing infection or development of a disease condition associated with a Gram-positive bacterial infection. | 11-18-2010 |
20100280118 | Methods for treating substance dependence - The present invention provides methods for treating alcohol dependence and preventing relapse in subjects in protracted alcohol abstinence. Also provided are methods for treating subjects suffering from cannabis dependence. Typically, these methods entail administering to the subjects in need of treatment a therapeutically effective amount of gabapentin, an analog of gabapentin, or pharmaceutically acceptable salt thereof. | 11-04-2010 |
20100267719 | Enhanced Indolinone Based Protein Kinase Inhibitors - Alpha-hydroxy-omega-(2-oxo-indolylidenemethyl-pyrrole-3′-carbonyl)amino alkanoic acid and amide derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer. | 10-21-2010 |
20100267141 | CHEMICAL APPROACHES FOR GENERATION OF INDUCED PLURIPOTENT STEM CELLS - The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency. | 10-21-2010 |
20100247492 | METHODS FOR THE DETECTION OF CIRCULATING TUMOR CELLS - The present invention provides methods for revealing, detecting, and analyzing circulating tumor cells in the blood of a subject. Revealing detectable circulating tumor cells allows for early stage detection and diagnosis in addition to long term prognosis in subjects with cancer. Additionally, enrichment allows for robust detection and clinically meaningful analysis of low volume samples for use in clinical settings as well as innovative methods for the treatment of cancers. | 09-30-2010 |
20100234400 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS - The present invention relates to methods and compositions for culturing embryonic stem (ES) cells. The methods relate to growing the ES cells in the presence of small molecules of formula (I) that maintain the pluripotency/self-renewal of the cells without feeder cells and LIF in serum-free conditions. These methods in part facilitate much more consistency in embryonic stem cell production, providing, for example, new avenues in the practical applications of embryonic stem cells in regenerative medicine. | 09-16-2010 |
20100233804 | GENERATION OF PLURIPOTENT STEM CELLS USING RECOMBINANT PROTEINS - The present invention provides for methods, compositions, and kits of producing an induced pluripotent stem cell from a mammalian non-pluripotent cell using exogenous transcription factors. | 09-16-2010 |
20100216750 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE - A series of substituted oxazole compounds having an alpha keto side chain at the 2 position and an aromatic, heteroaromatic or heterocycle substituent at the 5 position are disclosed. These compounds exhibit inhibition of fatty acid amid hydrolase and arc useful for treatment of malconditions involving that enzyme. | 08-26-2010 |
20100166710 | Compositions and Methods for Inducing Neuronal Differentiation - The present invention provides compositions and methods for inducing neuronal cell differentiation. | 07-01-2010 |
20100160618 | Expanding the eukaryotic genetic code - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided. | 06-24-2010 |
20100158917 | Methods for diagnosing cancer and decreasing metastasis by cancer cells - The invention provides a protein that is a tumor marker protein. This protein can be used to prepare antibodies that bind to the tumor marker protein. These antibodies can be used to reduce, or eliminate metastasis by cancer cells that produce the tumor marker protein. In addition, the invention provides methods that can be used to diagnose cancer, and metastasis by cancer cells. | 06-24-2010 |
20100144632 | TRUNCATED 24kDa BASIC FIBROBLAST GROWTH FACTOR - The invention relates to fragments of an amino acid sequence of mature, full length 24 kDa fibroblast growth factor-2 or an analog thereof. The fragments have an activity that inhibits the migration of cultured cells as well as inhibiting angiogenesis, tumor growth, or any other processes that involve the migration of cells in vivo. This fragment does not stimulate the proliferation of cells which is in contrast to activity shown by the mature, full-length 24 kDa fibroblast growth factor-2. The present invention also relates to a DNA molecule encoding the fragment, an expression vector and a transformed host containing the DNA molecule, and a method of producing the protein by culturing the transformed host. Moreover, the present invention relates to a therapeutic composition the 24 kDa fibroblast growth factor fragment and a pharmaceutically acceptable carrier. | 06-10-2010 |
20100137231 | 6"-AMINO-6"-DEOXYGALACTOSYLCERAMIDES - This invention relates to galactosylceramide compounds. | 06-03-2010 |
20100130476 | COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION - The present invention relates to compounds and compositions for inducing the expansion of pancreatic β-cells. The invention further relates to a use of these expanded pancreatic β-cells to reversibly expand pancreatic β-cells and other quiescent cells to overcome deficits associated with degenerative and/or autoimmune diseases. | 05-27-2010 |
20100113466 | OXAZOLE-PYRIDAZINE-OXAZOLE ALPHA-HELIX MIMETIC - There are provided alpha helix scaffolds mimicking i, i+3/i+4, i+7 or i+11 residues having the general structure oxazole-pyridazine-piperidine or oxazole-pyridazine-oxazole. The common pyridazine heterocycle originates from substituted or unsubstituted dimethyl 1,2,4,5-tetrazine-3,6-dicarboxylate. These scaffolds are synthetic counterparts of amphiphilic alpha helices having a hydrophilic face along one side and a hydrophobic face along the other side of the helix. | 05-06-2010 |
20100113328 | Targeted delivery to legumain-expressing cells - The present invention relates to new agents and methods useful for preventing, treating and diagnosing diseases such as cancer. For example, the invention relates to prodrug agents useful for targeting and delivering cytotoxic drugs to cancerous cells. | 05-06-2010 |
20100104555 | HCV neutralizing epitopes - The invention relates to modified hepatitis C virus E2 polypeptides that are effective in eliciting the production of cross-neutralizing antibodies against hepatitis C virus. The invention provides modified hepatitis C virus E2 polypeptides, preparations and pharmaceutical compositions containing them, as well as methods for using these modified E2 polypeptides. | 04-29-2010 |
20100098689 | 4-1 bb ligand in inflammatory diseases - The invention provides 4-IBBL blocking agents, as well as pharmaceutical compositions and articles of manufacture comprising such blocking agents as new therapeutic interventions for sustained inflammation. Thus, the invention also provides methods for reducing sustained production of tumor necrosis factor. | 04-22-2010 |
20100086532 | CHIMERIC ZINC FINGER RECOMBINASES OPTIMIZED FOR CATALYSIS BY DIRECTED EVOLUTION - The present invention is directed to chimeric recombinases comprising a serine recombinase operatively linked to a zinc finger nucleotide binding domain such that the chimeric recombinase protein catalyzes site-specific recombination at a DNA site specifically bound by the zinc finger nucleotide binding domain. The serine recombinase can be one of several naturally occurring serine recombinases. The invention also includes nucleic acids encoding the chimeric recombinases, vectors including the nucleic acids, host cells transformed or transfected with the vectors, methods of using the chimeric recombinases to carry out recombination, methods of using substrate-linked protein evolution to generate additional chimeric recombinases, methods of using the chimeric recombinases for gene therapy, and pharmaceutical compositions. | 04-08-2010 |
20100075931 | Substituted oxazole ketone modulators of fatty acid amide hydrolase - Certain oxazole ketone compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis). | 03-25-2010 |
20100056494 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES - The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with kinase activity, particularly malaria. | 03-04-2010 |
20100041028 | Zinc finger binding domains for GNN - Zinc finger-nucleotide binding polypeptides having binding specificity for target nucleotides containing one or GNN triplets are provided. Compositions containing such polypeptides and the use of such polypeptides and compositions for regulating gene expression are also provided. | 02-18-2010 |
20100022549 | ALPHA-HELIX MIMETIC WITH FUNCTIONALIZED PYRIDAZINE - The synthesis of new α-helix scaffolds mimicking i, i+3 or i+4, i+7 residues, was accomplished. The common pyridazine heterocycle originates from the easily available dimethyl pyridazine-3,6-dicarboxylate building block. These scaffolds may be thought of as synthetic counterparts of amphiphilic α-helices having a hydrophilic face along one side and a hydrophobic face along the other side of the helix. | 01-28-2010 |
20100022533 | COMPOSITIONS AND METHODS FOR INDUCING CELL DEDIFFERENTIATION - The present invention provides compounds, compositions and methods for dedifferentiating lineage committed mammalian cells into stem cells. The present invention also provides methods of inducing dedifferentiation of lineage committed mammalian cells into stem cells, which can be further differentiated into various lineage committed cells. Methods of identifying additional compounds useful for inducing dedifferentiation of lineage committed cells into stem cells are also provided. | 01-28-2010 |
20100021487 | VACCINES AND METHODS FOR CONTROLLING ADIPOSITY - The invention features immunoconjugates for impeding weight gain and treating obesity in a subject. The immuno-conjugates comprise particular ghrelin polypeptides and a suitable carrier moiety. | 01-28-2010 |
20100015595 | Phage Particle Diagnostic Reagents - The present invention relates to novel methods for detecting a member of a known binding pair in a sample, including a cell, where one member of the pair (termed the “receptor”) is expressed by a bacteriophage, which phage is then used to detect the presence of the other member of the pair (termed the “ligand” or “target”). Rather than detecting the binding of the phage using antibody-based technology, the present invention relates to detecting marker molecule associated with the phage. In one aspect, the invention relates to identifying an antigen-bearing moiety (e.g., a red blood cell antigen) of interest present on a cell, e.g., a red blood cell, using antibody-displaying bacteriophage, as well as detecting anti-red blood cell auto- or alloantibodies and/or complement in a sample, using antiglobulin reagent-displaying bacteriophage and detecting a marker molecule associated with the phage. In one aspect, the phenotype of the phage is not linked with the genotype of the phage. | 01-21-2010 |
20100009425 | Glycoprotein synthesis - Methods for making glycoproteins, both in vitro and in vivo, are provided. One method involves incorporating an unnatural amino acid into a protein and attaching one or more saccharide moieties to the unnatural amino acid. Another method involves incorporating an unnatural amino acid that includes a saccharide moiety into a protein. Proteins made by both methods can be further modified with additional sugars. | 01-14-2010 |
20100003711 | Methods to identify therapeutic agents - As illustrated herein, cholesterol is oxidized when it is present in atherosclerotic plaques. This reaction generates cholesterol oxidation or ozonation products that can act as chemotactic attractants of macrophages, can promote differentiation of monocytes into macrophages and can increase expression of E-selectin and Class A scavenger receptor (SR-A). The present application is directed to methods of using such cholesterol ozonoation products to identify agents that can be used to treat atherosclerosis and other inflammatory artery diseases. | 01-07-2010 |
20090317836 | Methods for Detection of Circulating Tumor Cells and Methods of Diagnosis of Cancer in Mammalian Subject - Methods are provided for detecting circulating tumor cells in a mammalian subject. Methods of diagnosing cancer in a mammalian subject are provided. The methods of detection or diagnosis indicate the presence of metastatic cancer or early stage cancer. | 12-24-2009 |
20090306310 | Method of using click chemistry to functionalize dendrimers - A library of functionalized dendritic macromolecules was prepared in extremely high yields using no protecting group strategies and with only minimal purification steps through the use of copper(I)-catalyzed 1,3-dipolar cycloaddition of azides and terminal acetylenes. | 12-10-2009 |
20090305382 | ALKOXY INDOLINONE BASED PROTEIN KINASE INHIBITORS - Alkoxy indolinone based acid and amide derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer. | 12-10-2009 |
20090305244 | Selection, Propagation and Use of Mosaic Aneuploid Stem Cells - The distribution of cell karyotypes within a population of cells can determine the phenotype and ability of stem cells to differentiate into desired cell types, to function normally, as well as represent risk for adverse events like cancer. Therefore, determination of the aneuploid mosaic status of a cell population is useful in identifying and/or maintaining desirable traits and eliminating undesirable traits in stem cells, and for defining them at the level of their chromosomal complement. | 12-10-2009 |
20090298835 | NOVEL SCAFFOLDS FOR ALPHA-HELIX MIMICRY - Functionalized pyridazine derivatives having a low molecular weight and pharmaceutical compositions thereof are useful as alpha-helix mimetics and for treating conditions and/or disorders mediated by alpha-helix-binding receptors and proteins. | 12-03-2009 |
20090298124 | Site-specific incorporation of redox active amino acids into proteins - Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases, which incorporate redox active amino acids into proteins are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with redox active amino acids using these orthogonal pairs. | 12-03-2009 |
20090280545 | MOLECULE PRODUCTION BY PHOTOSYNTHETIC ORGANISMS - The present invention provides compositions and methods for producing products by photosynthetic organisms. The photosynthetic organisms are genetically modified to effect production, secretion, or both, of products. The methods and compositions are particularly useful in the petrochemical industry. | 11-12-2009 |
20090275064 | Methods to identify therapeutic agents - As illustrated herein, cholesterol is oxidized when it is present in atherosclerotic plaques. This reaction generates cholesterol oxidation or ozonation products that can act as chemotactic attractants of macrophages, can promote differentiation of monocytes into macrophages and can increase expression of E-selectin and Class A scavenger receptor (SR-A). The present application is directed to methods of using such cholesterol ozonation products to identify agents that can be used to treat atherosclerosis and other inflammatory artery diseases. | 11-05-2009 |
20090270421 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE - Potent inhibitors of fatty acid amide hydrolase (FAAH) are constructed having K | 10-29-2009 |
20090263376 | Breaking immunological toterance with a genetically encoded unnatural amino acid - The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against a version of a target moiety having one or more unnatural amino acid which antibody is cross reactive with the natural target moiety. | 10-22-2009 |
20090253169 | Use of genetically modified organisms to generate biomass degrading enzymes - The present invention provides a method and compositions for high throughput screening of genetically modified photosynthetic organisms for plasmic state. The present invention provides methods of producing one or more proteins, including biomass degrading enzymes in a plant. Also provided are the methods of producing biomass degradation pathways in alga cells, particularly in the chloroplast. Single enzymes or multiple enzymes may be produced by the methods disclosed. The methods disclosed herein allow for the production of biofuel, including ethanol. | 10-08-2009 |
20090246766 | High throughput screening of genetically modified photosynthetic organisms - The present invention provides a method and compositions for high throughput screening of genetically modified photosynthetic organisms for plasmic state. The present invention provides methods of producing one or more proteins, including biomass degrading enzymes in a plant. Also provided are the methods of producing biomass degradation pathways in alga cells, particularly in the chloroplast. Single enzymes or multiple enzymes may be produced by the methods disclosed. The methods disclosed herein allow for the production of biofuel, including ethanol. | 10-01-2009 |
20090217400 | Enzymes, cells and methods for site specific recombination at asymmetric sites - The present invention relates to enzymes, compositions and methods for catalyzing asymmetric recombination of non-palindromic recombination sites in a cell free system, in isolated cells or in living organisms. The enzymes and methods of the invention are suitable for mediating specific recombinations between DNA sequences comprising specific recombination sites without being limited to strict palindromic symmetry within each recombination site. | 08-27-2009 |
20090215117 | Site specific incorporation of keto amino acids into proteins - Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases, which incorporate keto amino acids into proteins are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with keto amino acids using these orthogonal pairs. | 08-27-2009 |
20090214532 | ANKTM1, A Cold-Activated TRP-Like Channel Expressed in Nociceptive Neurons - The methods and compositions of the invention are based on a method for measuring nociceptive responses in vertebrates, including humans and other mammals utilizing a newly discovered thermoreceptor belonging to the Transient Receptor Potential (TRP) family of non-selective cation channels that participates in thermosensation and pain. This receptor, designated ANKTM1, is associated with nociceptive pain, such as hyperalgesia. Accordingly, the invention provides isolated polypeptides and polynucleotides associated with nociception as well as methods for identifying or screening agents that modulate nociception. | 08-27-2009 |
20090209573 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS - The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I. | 08-20-2009 |
20090208994 | GENETIC INCORPORATION OF 3-AMINOTYROSINE INTO REDUCTASES - This invention provides reductase proteins that comprise NH | 08-20-2009 |
20090203605 | Methods For Treating A Condition Characterized By Dysfunction In Protein Homeostasis - Methods are provided for treating conditions characterized by dysfunction in protein homeostasis in a patient in need thereof. A method for treating a condition characterized by dysfunction in protein homeostasis in a patient in need thereof is provided which comprises administering to the patient a proteostasis regulator in an amount effective to improve or restore protein homeostasis, and to reduce or eliminate the condition in the patient or to prevent its occurrence or recurrence. The condition can be a loss of function disorder such as a lysosomal storage disease, or a gain of function disorder such as an aging associated disease. | 08-13-2009 |
20090202519 | Compositions and methods for treating gram positive bacterial infection in a mammalian subject - Compositions and methods are provided for treating Gram positive bacterial infection in a mammalian subject. Compositions and methods are further provided for treating Gram positive bacterial skin infection in the mammalian subject. Compositions and method are provided that comprise administering to the mammalian subject an effective amount of a compound that activates Scd1 gene expression or activates Scd1 gene product. | 08-13-2009 |
20090197895 | OXAZOLE-PYRROLE-PIPERAZINE ALPHA-HELIX MIMETIC - Amphiphilic α-helix mimetics are provided. These compounds are constructed using an oxazole-pyrrole-piperazine (OPP) scaffold. The amphiphilic α-helix mimetics are also employable for making libraries and for treating diseases or conditions effected by the inhibition or disruption of interactions with the alpha helix of a protein. | 08-06-2009 |
20090197339 | In vivo unnatural amino acid expression in the methylotrophic yeast pichia pastoris - The invention provides orthogonal translation systems for the production of polypeptides comprising unnatural amino acids in methylotrophic yeast such as | 08-06-2009 |
20090186827 | Process of inhibiting cell death in injured cartilage - Processes for inhibiting apoptotic cell death and glycosaminoglycan release from injured cartilage is provided. Inhibition is accomplished using caspase inhibitors. | 07-23-2009 |
20090182151 | Method for making amphiphilic dendrimers - A series of AB-type amphiphilic dendritic polyesters have been prepared divergently, in which two hybrids were coupled via the copper(1)-catalyzed triazole formation. | 07-16-2009 |
20090181402 | COMPOSITIONS AND METHODS FOR COUPLING A PLURALITY OF COMPOUNDS TO A SCAFFOLD - Compositions and methods are provided for coupling a plurality of compounds to a scaffold. Compositions and methods are further provided for catalyzing a reaction between at least one terminal alkyne moiety and at least one azide moiety, wherein one moiety is attached to the compound and the other moiety is attached to the scaffold, forming at least one triazole thereby. | 07-16-2009 |
20090175882 | METHODS AND COMPOSITIONS FOR TREATING HYPERALGESIA - This invention provides compounds which specifically inhibit TRPA1 but not other members of the thermoTRP ion channel family. Also provided in the invention are methods of using TRPA1-specific inhibitors to treat or alleviate pains mediated by noxious mechanosensation. | 07-09-2009 |
20090175873 | Inhibiting tumor cell invasion, metastasis and angiogenesis - The present invention relates to new compositions and methods useful for preventing, treating and diagnosing metastatic and/or invasive cancer and undesirable angiogenesis. For example, the invention relates to inhibitors of proteases that are specifically expressed in tumors, prodrugs activated in the tumor microenvironment and methods for using those inhibitors and prodrugs to inhibit angiogenesis and tumor cell invasion. | 07-09-2009 |
20090163368 | Directed evolution using proteins comprising unnatural amino acids - The invention provides methods and compositions for screening polypeptide libraries that include variants comprising unnatural amino acids. In addition, the invention provides vector packaging systems and methods for packaging a nucleic acid in a vector. Compositions of vectors produced by the methods and systems are also provided | 06-25-2009 |
20090148887 | GENETICALLY ENCODED BORONATE AMINO ACID - Provided are compositions comprising an aminoacyl tRNA synthetase that selectively recognizes a boronic amino acid. Methods of incorporating a boronic amino acid into a target polypeptides and target polypeptides produced by the methods are also provided. Methods of producing a protein, which methods comprise site-specifically encoding a boronic amino acid residue into a mutant protein and selectively converting the boronic amino acid residue into a natural amino acid residue are provided. Also provided are compositions comprising a solid phase matrix covalently bound to a polypeptide through a boronic amino acid residue. In addition, compositions comprising a purified population of polypeptide molecules that each comprise a borono amino acid at a selected site are provided. | 06-11-2009 |
20090136518 | Compositions and methods to reduce mutagenesis - The present invention provides methods and compositions for said inhibition of drug resistance. In one embodiment, said invention provides methods and compositions for said inhibition of antibiotic resistance. The invention generally involves said administration of achaogens, agents that inhibit said mutational process, to inhibit said evolution of drug resistance. Also, described herein are compositions that are suitable for use as achaogens. | 05-28-2009 |
20090110672 | Angiogenic Tyrosyl tRNA Synthetase Compositions and Methods - The present invention provides an isolated tyrosyl tRNA synthetase (TyrRS) polypeptide variant which comprises (a) a Rossmann fold region or a portion thereof, preferably including an 5 coil; and (b) an anticodon recognition domain or portion thereof, preferably including an 14 coil. Preferably, the 5 coil and the 14 coil have a greater spatial separation in the tertiary structure of the variant compared to the corresponding spatial separation in native human TyrRS. The variant preferably comprises an amino acid residue sequence identity of at least about 50% compared to the amino acid residue sequence of human TyrRS (SEQ ID NO: 3), includes at least one non-conservative amino acid residue sequence of human TyrRS, and preferably presents an exposed ELR motif in the 5 coil on an external portion of the tertiary structure of the polypeptide. A preferred TyrRS protein variant comprises the amino acid residue sequence of SEQ ID NO: 4 or a portion thereof. The proteins and protein fragments of the invention are angiogenic and are useful for stimulating angiogenesis in mammalian tissues. | 04-30-2009 |
20090098599 | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use - The present invention relates to methods for gene therapy, especially to adenovirus-based gene therapy, and related cell lines and compositions. In particular, novel nucleic acid constructs and packaging cell lines are disclosed, for use in facilitating the development of high-capacity and targeted vectors. The invention also discloses a variety of high-capacity adenovirus vectors and related compositions and kits including the disclosed cell lines and vectors. Finally, the invention discloses methods of preparing and using the disclosed vectors, cell lines and kits. | 04-16-2009 |